Related Experiment Video
Updated: Jan 3, 2026

Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
Engineering microglia as intraoperative optical imaging agent vehicles potentially for fluorescence-guided surgery in
Ling Guo1, Xiaochen Zhang1, Runxiu Wei1
1School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou, 510006, P.R. China. wangcf6@mail.sysu.edu.cn fengmin@mail.sysu.edu.cn and Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, University Town, Guangzhou, 510006, P.R. China.
Abstract:
Surgical resection currently remains the mainstay of treatment for patients with gliomas of any grade. The maximum extent of surgical resection is associated with a long-term disease control; however, maximal resection of the brain tumor possibly results in additional neurological deficits. Therefore, improving the precision in brain tumor surgery by visual identification and screening of tumor cells can help to tackle this devastating disease. In the present study, BV2 microglial cells were engineered by iron oxide-nanoparticle stimulation as intraoperative optical imaging agent vehicles and loaded with near-infrared fluorescent dye DiD (DiDBV2-Fe) potentially for fluorescence-guided brain tumor surgery. Activation of BV2 microglial cells by citrate-stabilized iron oxide nanoparticles at a concentration of 62.5 μg mL-1 significantly inhibited M2 markers (arginase-1 and CD206), which is able to minimize risks of the immunosuppressive effects caused by the M2-like phenotype of microglial cells. Meanwhile, activated BV2 microglial cells showed up-regulation of arylsulfatase A, apolipoprotein E, transferrin, and ferritin heavy chain-1 gene expression that tends to promote microglia transport across the blood-brain barrier (BBB). Compared to DiDBV2 without iron oxide activation, DiDBV2-Fe indicated strong tumor tropism in response to monocyte chemoattractant protein-1 (CCL2) secreted by U87MG tumor cells. In vivo experiments proved that DiDBV2-Fe efficiently crossed the BBB and more than 90% fluorescence intensity generated by activated microglial cells was detected in the brain when administered through the carotid artery in an orthotopic glioblastoma mouse model. Notably, DiDBV2-Fe produced clear tumor border demarcation on near-infrared imaging and exhibited a superior tumor-to-brain fluorescence ratio to commercial 5-aminolevulinic acid. Accumulated DiDBV2-Fe induced a strong fluorescence signal in brain tumor tissue for a prolonged period (4-24 h), which is beneficial to perform complex and time-consuming brain operations. Overall, our study suggests that this newly engineered microglial cell has promise for enabling more accurate brain tumor imaging for fluorescence-guided resections.
Insights
Engineered microglial cells loaded with near-infrared dye show promise for precise brain tumor surgery. These DiDBV2-Fe cells cross the blood-brain barrier, clearly marking tumor borders for improved fluorescence-guided resection.
Area of Science:
- Biomedical Engineering
- Neuroscience
- Oncology
Background:
- Surgical resection is the primary treatment for gliomas, but maximizing tumor removal can cause neurological deficits.
- Improving precision in brain tumor surgery through visual identification of tumor cells is crucial.
Purpose of the Study:
- To engineer BV2 microglial cells as intraoperative optical imaging agents for fluorescence-guided brain tumor surgery.
- To evaluate the efficacy of DiDBV2-Fe as an imaging agent for detecting brain tumors.
Main Methods:
- BV2 microglial cells were stimulated with iron oxide nanoparticles and loaded with the near-infrared fluorescent dye DiD (DiDBV2-Fe).
- The study assessed the impact of iron oxide activation on microglial cell markers and their ability to cross the blood-brain barrier (BBB).
- In vivo experiments used an orthotopic glioblastoma mouse model to evaluate DiDBV2-Fe's tumor tropism and fluorescence imaging capabilities.
Main Results:
- Iron oxide activation of BV2 cells inhibited immunosuppressive M2 markers and promoted BBB transport.
- DiDBV2-Fe demonstrated strong tumor tropism in response to CCL2 secreted by U87MG tumor cells.
- In vivo, DiDBV2-Fe efficiently crossed the BBB, with over 90% fluorescence detected in the brain, clearly demarcating tumor borders with a superior tumor-to-brain fluorescence ratio compared to 5-aminolevulinic acid.
Conclusions:
- Engineered DiDBV2-Fe microglial cells show potential as an effective intraoperative imaging agent for brain tumors.
- This approach can enhance the precision of fluorescence-guided tumor resections, potentially improving patient outcomes.
- The prolonged fluorescence signal (4-24 h) is advantageous for complex surgical procedures.

